Eli Lilly and Company has reported detailed findings from the ACHIEVE-3 Phase III trial comparing the efficacy and safety of orforglipron and oral semaglutide in adults with type 2 diabetes ...

Ahead of Rare Disease Day, Abigail Beaney, editor of Clinical Trials Arena, spoke with Robert Barrie, editor of Pharmaceutical Technology and Frankie Fattorini, reporter for Pharmaceutical Technology ...

Mahzi Therapeutics has dosed the first patient in its Phase I/II UNITE study assessing MZ-1866, an investigational gene ...

Moderna has announced that the FDA will initiate the review of its seasonal influenza vaccine candidate, mRNA-1010.

Novo Nordisk and United Laboratories’ jointly developed triple G drug has achieved a 19.7% weight loss in a Phase II trial in ...

Patients with HIV showed lower cases of steatotic liver disease when switched to ViiV Healthcare’s Dovato compared to ...

In the trial, CagriSema appeared to have a safe and well-tolerated profile. The most common adverse events with CagriSema ...

C4 Therapeutics has dosed the first patient in its Phase II MOMENTUM trial of cemsidomide, an oral IKZF1/3 degrader, combined with dexamethasone for patients with RRMM.

The US Food and Drug Administration (FDA) has issued more information to sponsors regarding its “plausible mechanism pathway” ...

Jaguar Gene Therapy has completed Cohort I dosing of its first-in-human clinical trial investigating JAG201 for patients with SHANK3 haploinsufficiency.

Revati Tatake, Global head of Pharma and Competitive Intelligence, GlobalData, speaks about the latest clinical trial, drug development and licensing trends from China at the Outsourcing in Clinical ...

Teva Pharmaceuticals and Sanofi’s monoclonal antibody (mAb) has shown durable clinical and endoscopic efficacy in a Phase IIb ...